Katkin Keith 4
4 · Syndax Pharmaceuticals Inc · Filed Oct 7, 2022
Insider Transaction Report
Form 4
Katkin Keith
Director
Transactions
- Sale
Common Stock
2022-10-06$25.90/sh−9,117$236,139→ 32,000 total - Exercise/Conversion
Common Stock
2022-10-06$7.88/sh+20,782$163,762→ 52,782 total - Sale
Common Stock
2022-10-06$25.90/sh−20,782$538,273→ 32,000 total - Exercise/Conversion
Common Stock
2022-10-06$8.93/sh+9,117$81,415→ 41,117 total - Exercise/Conversion
Stock Options (Right to buy)
2022-10-06−9,117→ 0 totalExercise: $8.93Exp: 2028-05-23→ Common Stock (9,117 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2022-10-06−20,782→ 0 totalExercise: $7.88Exp: 2029-06-10→ Common Stock (20,782 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 73,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
- [F2]The sale prices ranged from $25.0000 to $26.4600.
- [F3]This option is fully vested.